COMPLETED

Urolithin A Supplementation in Middle-aged Adults With Obesity

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The goal of this clinical trial is to learn about the effect of urolithin A, a dietary supplement, on blood flow in middle-aged adults with obesity. The main question it aims to answer is: - Does urolithin A supplementation improve blood flow in large and small blood vessels in middle-aged adults with obesity? Participants will be asked to: * Take the dietary supplement daily for 4 weeks * Attend two study visits to have their blood vessels checked, answer questionnaires, and give a sample of blood Researchers will compare people who took the dietary supplement with others who took a placebo to see if the blood flow in the blood vessels improved.

Official Title

Urolithin A Supplementation to Improve Endothelial and Cerebrovascular Function in Middle-aged Adults With Obesity

Quick Facts

Study Start:2023-10-02
Study Completion:2025-05-14
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:COMPLETED

Study ID

NCT05921266

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:40 Years to 64 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT
Inclusion CriteriaExclusion Criteria
  1. * Age: 40-64 years old, inclusive
  2. * Obesity \[BMI ≥30 kg/m2\]
  3. * Ability to read, write, and speak English
  4. * Competence to provide written informed consent
  1. * Pregnant or breastfeeding women, or women who intend to become pregnant within the study period
  2. * History of uncontrolled hypertension
  3. * History of uncontrolled type 1 or type 2 diabetes mellitus
  4. * Significant cardiac disease or chest pain in the last 6 months
  5. * History of untreated depression or anxiety
  6. * History of cognitive impairment
  7. * History of uncontrolled significant GI disease (e.g., IBS, Crohn's disease)
  8. * Allergy or intolerance to one or more of the intervention components
  9. * Undergoing treatment for active cancer
  10. * History of neurodegenerative disorders (e.g., multiple sclerosis)
  11. * Presence of any condition affecting swallowing ability
  12. * Any other medical condition that the investigators deem would adversely affect the participant's safety or ability to complete the study

Contacts and Locations

Principal Investigator

Andriy Yabluchanskiy, MD, PhD
PRINCIPAL_INVESTIGATOR
University of Oklahoma Health Science Center

Study Locations (Sites)

Translational GeroScience Laboratory - O'Donoghue Research Building
Oklahoma City, Oklahoma, 73117
United States

Collaborators and Investigators

Sponsor: University of Oklahoma

  • Andriy Yabluchanskiy, MD, PhD, PRINCIPAL_INVESTIGATOR, University of Oklahoma Health Science Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-10-02
Study Completion Date2025-05-14

Study Record Updates

Study Start Date2023-10-02
Study Completion Date2025-05-14

Terms related to this study

Keywords Provided by Researchers

  • Obesity
  • Urolithin A
  • Middle aged
  • Flow-mediated dilation
  • Endothelial function
  • fNIRS
  • Nitric oxide
  • Vascular contributions to cognitive impairment and dementia

Additional Relevant MeSH Terms

  • Obesity
  • Vascular Dementia
  • Cognitive Impairment